Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04570865

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04570865
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04570865. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-01 (anticipated); primary completion 2021-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®
Acronym
DAPA-MEMS
Condition
Heart Failure, Systolic
Intervention (Drug)
Dapagliflozin
Intervention (Device)
CardioMEMS
Lead sponsor
Scripps Health (class: other)

Record details

Record id
cardio:ct-nct04570865
Content hash
f6781c6e0dc58f1c61775ff2b0fdc506fa696e2338d55f78dc4595f7df7cac01